Mankind Pharma launches drug to treat black fungus

PTI New Delhi | Updated on June 10, 2021

Receives DCGI approval; AIIMS, ICMR recommend the drug’s use against black fungus

Mankind Pharma on Thursday said it has launched Posaconazole Gastro resistant tablets, used to treat black fungus, in the country.

The company has launched the drug under the brand name Posaforce 100.

Also read: Karnataka to cap Mucormycosis treatment cost in private hospitals

“As the cases of black fungus are increasing day by day, the product has been launched to fight against this infection. The drug firm always strives to launch affordable medicines with an endeavour to achieve the best quality standards in the pharmaceutical industry,” Mankind Pharma said in a statement.

The country has seen more than 12,000 cases of deadly black fungus (mucormycosis) so far with Gujarat, Maharashtra, Andhra Pradesh, Madhya Pradesh and Telangana, accounting for the maximum number of cases.

Posaconazole has been found to be a safer and effective drug of choice for the management of the disease. The drug has received approval from the Drug Controller General of India (DCGI), the drug maker noted. Besides, AIIMS and ICMR have also recommended use of Posaconazole as an effective option for the management of mucormycosis, it added.

The antifungal drug with minimal potential for nephrotoxicity and excellent tolerability profile has been cleared by the USFDA.

Black fungus commonly occurs in soil, and airborne spores often produce infections.

Life threatening conditions like severe Covid-19 infection; prolonged immune suppression or reduced immunity, uncontrolled diabetes mellitus or haematological malignancies and even contamination of open wounds with Mucorales can lead to this infection.

Published on June 10, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.